Literature DB >> 19101824

Homozygosity of MSH2 c.1906G-->C germline mutation is associated with childhood colon cancer, astrocytoma and signs of Neurofibromatosis type I.

Helen Toledano1, Yael Goldberg, Inbal Kedar-Barnes, Hagit Baris, Rinnat M Porat, Chen Shochat, Dani Bercovich, Eli Pikarsky, Israela Lerer, Isaac Yaniv, Dvorah Abeliovich, Tamar Peretz.   

Abstract

Hereditary non-polyposis colorectal cancer is a cancer predisposition syndrome known to be caused by heterozygous germline mutations in DNA mismatch repair genes (MMR) most commonly hMLH1, hMSH2, hMSH6. Heterozygous mutations in one of these genes confer an increased risk, mainly for colon and endometrial cancer. Recently, several publications identified that biallelic mutations in the MMR genes are associated with a more severe phenotype, including childhood malignancies and signs of neurofibromatosis type I (NF1). We report on a non-consanguineous Ashkenazi Jewish family with two affected siblings with features of NF1, colon cancer and astrocytoma at age 13 and 14. Their mother developed endometrial cancer at age 54. Their father had leukoplakia of the vocal cords with a family history of pancreatic cancer. Molecular and pathology studies were done on the tumor tissue and on genomic DNA of family members. Tumor testing demonstrated a high degree of microsatellite instability (MSI analysis), expression of MLH1 and absence of expression of both MSH2 and MSH6 proteins. A biallelic c.1906G > C (p.A636P) mutation in the hMSH2 gene was detected in the blood of one affected child. Parental genetic testing showed that each parent was heterozygote for the mutation. The c.1906G > C mutation is a founder mutation in the Ashkenazi Jewish population. To our knowledge this is the first report of homozygosity for this founder mutation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19101824     DOI: 10.1007/s10689-008-9227-3

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  34 in total

1.  Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein.

Authors:  Saara Ollila; Laura Sarantaus; Reetta Kariola; Philip Chan; Heather Hampel; Elke Holinski-Feder; Finlay Macrae; Maija Kohonen-Corish; Anne-Marie Gerdes; Päivi Peltomäki; Elisabeth Mangold; Albert de la Chapelle; Marc Greenblatt; Minna Nyström
Journal:  Gastroenterology       Date:  2006-08-22       Impact factor: 22.682

Review 2.  [HNPCC syndrome, microsatellite instability and NF1 gene alteration].

Authors:  A Puisieux
Journal:  Bull Cancer       Date:  1999-10       Impact factor: 1.276

3.  The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.

Authors:  W D Foulkes; I Thiffault; S B Gruber; M Horwitz; N Hamel; C Lee; J Shia; A Markowitz; A Figer; E Friedman; D Farber; C M T Greenwood; J D Bonner; K Nafa; T Walsh; V Marcus; L Tomsho; J Gebert; F A Macrae; C L Gaff; B Bressac-De Paillerets; P K Gregersen; J N Weitzel; P H Gordon; E MacNamara; M-C King; H Hampel; A De La Chapelle; J Boyd; K Offit; G Rennert; G Chong; N A Ellis
Journal:  Am J Hum Genet       Date:  2002-11-26       Impact factor: 11.025

Review 4.  Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review.

Authors:  H T Lynch; T C Smyrk; P Watson; S J Lanspa; J F Lynch; P M Lynch; R J Cavalieri; C R Boland
Journal:  Gastroenterology       Date:  1993-05       Impact factor: 22.682

5.  MSH2 deficient mice are viable and susceptible to lymphoid tumours.

Authors:  A H Reitmair; R Schmits; A Ewel; B Bapat; M Redston; A Mitri; P Waterhouse; H W Mittrücker; A Wakeham; B Liu
Journal:  Nat Genet       Date:  1995-09       Impact factor: 38.330

6.  A homozygous MSH6 mutation in a child with café-au-lait spots, oligodendroglioma and rectal cancer.

Authors:  Fred H Menko; Gertjan L Kaspers; Gerrit A Meijer; Kathleen Claes; Johanna M van Hagen; Johan J P Gille
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

7.  Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues.

Authors:  F S Leach; K Polyak; M Burrell; K A Johnson; D Hill; M G Dunlop; A H Wyllie; P Peltomaki; A de la Chapelle; S R Hamilton; K W Kinzler; B Vogelstein
Journal:  Cancer Res       Date:  1996-01-15       Impact factor: 12.701

8.  Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer.

Authors:  M Fujita; T Enomoto; K Yoshino; T Nomura; G S Buzard; M Inoue; Y Okudaira
Journal:  Int J Cancer       Date:  1995-12-20       Impact factor: 7.396

9.  Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-deficient cell type.

Authors:  Qing Wang; Gilles Montmain; Eric Ruano; Meena Upadhyaya; Sandra Dudley; R Michael Liskay; Stephen N Thibodeau; Alain Puisieux
Journal:  Hum Genet       Date:  2002-11-21       Impact factor: 4.132

10.  Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis.

Authors:  H F Vasen; J T Wijnen; F H Menko; J H Kleibeuker; B G Taal; G Griffioen; F M Nagengast; E H Meijers-Heijboer; L Bertario; L Varesco; M L Bisgaard; J Mohr; R Fodde; P M Khan
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

View more
  9 in total

1.  Constitutional mismatch repair-deficiency syndrome.

Authors:  Katharina Wimmer; Christian P Kratz
Journal:  Haematologica       Date:  2010-05       Impact factor: 9.941

2.  Lynch Syndrome in high risk Ashkenazi Jews in Israel.

Authors:  Yael Goldberg; Inbal Kedar; Revital Kariiv; Naama Halpern; Morasha Plesser; Ayala Hubert; Luna Kaduri; Michal Sagi; Israela Lerer; Dvorah Abeliovich; Tamar Hamburger; Aviram Nissan; Hanoch Goldshmidt; Irit Solar; Ravit Geva; Hana Strul; Guy Rosner; Hagit Baris; Zohar Levi; Tamar Peretz
Journal:  Fam Cancer       Date:  2014-03       Impact factor: 2.375

3.  Predictive genetic testing in children: constitutional mismatch repair deficiency cancer predisposing syndrome.

Authors:  Zandrè Bruwer; Ursula Algar; Alvera Vorster; Karen Fieggen; Alan Davidson; Paul Goldberg; Helen Wainwright; Rajkumar Ramesar
Journal:  J Genet Couns       Date:  2013-10-15       Impact factor: 2.537

4.  Gastrointestinal Findings in the Largest Series of Patients With Hereditary Biallelic Mismatch Repair Deficiency Syndrome: Report from the International Consortium.

Authors:  Melyssa Aronson; Steven Gallinger; Zane Cohen; Shlomi Cohen; Rina Dvir; Ronit Elhasid; Hagit N Baris; Revital Kariv; Harriet Druker; Helen Chan; Simon C Ling; Paul Kortan; Spring Holter; Kara Semotiuk; David Malkin; Roula Farah; Alain Sayad; Brandie Heald; Matthew F Kalady; Lynette S Penney; Andrea L Rideout; Mohsin Rashid; Linda Hasadsri; Pavel Pichurin; Douglas Riegert-Johnson; Brittany Campbell; Doua Bakry; Hala Al-Rimawi; Qasim Kholaif Alharbi; Musa Alharbi; Ashraf Shamvil; Uri Tabori; Carol Durno
Journal:  Am J Gastroenterol       Date:  2016-01-05       Impact factor: 10.864

Review 5.  A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes.

Authors:  Sarah Scollon; Amanda Knoth Anglin; Martha Thomas; Joyce T Turner; Kami Wolfe Schneider
Journal:  J Genet Couns       Date:  2017-03-29       Impact factor: 2.537

6.  An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC.

Authors:  Yael Goldberg; Rinnat M Porat; Inbal Kedar; Chen Shochat; Daliah Galinsky; Tamar Hamburger; Ayala Hubert; Hana Strul; Revital Kariiv; Liat Ben-Avi; Moran Savion; Eli Pikarsky; Dvorah Abeliovich; Dani Bercovich; Israela Lerer; Tamar Peretz
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

Review 7.  The Challenge of Diagnosing Constitutional Mismatch Repair Deficiency Syndrome in Brain Malignancies from Young Individuals.

Authors:  Cristina Carrato; Carolina Sanz; Ana María Muñoz-Mármol; Ignacio Blanco; Marta Pineda; Jesús Del Valle; Estela Dámaso; Manel Esteller; Eva Musulen
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

8.  TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient.

Authors:  Juliana Giacomazzi; Simone Selistre; Juliana Duarte; Jorge Pinto Ribeiro; Paulo J C Vieira; Gabriel de Souza Macedo; Cristina Rossi; Mauro Czepielewski; Cristina Brinkmann Oliveira Netto; Pierre Hainaut; Patricia Ashton-Prolla
Journal:  BMC Cancer       Date:  2013-04-09       Impact factor: 4.430

Review 9.  Cancer Predisposition Syndromes and Medulloblastoma in the Molecular Era.

Authors:  Roberto Carta; Giada Del Baldo; Evelina Miele; Agnese Po; Zein Mersini Besharat; Francesca Nazio; Giovanna Stefania Colafati; Eleonora Piccirilli; Emanuele Agolini; Martina Rinelli; Mariachiara Lodi; Antonella Cacchione; Andrea Carai; Luigi Boccuto; Elisabetta Ferretti; Franco Locatelli; Angela Mastronuzzi
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.